Fundraising Fox恒赛生物
1 known investors
Find your way into 恒赛生物
Sign up to see every warm intro you have to 恒赛生物
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 恒赛生物 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Kousai (恒赛生物), founded in 2018, is a Chinese biotech company developing and commercializing therapeutic dendritic cell (DC) vaccines for conditions such as relapsed/refractory tumors, chronic viral infections, and autoimmune diseases. It operates the Eco-DCVax platform and its lead pipeline candidate targets EBV-associated hematological and solid tumors.
Investors · 1
Frequently asked questions
- What does 恒赛生物 do?
- Kousai (恒赛生物), founded in 2018, is a Chinese biotech company developing and commercializing therapeutic dendritic cell (DC) vaccines for conditions such as relapsed/refractory tumors, chronic viral infections, and autoimmune diseases. It operates the Eco-DCVax platform and its lead pipeline candidate targets EBV-associated hematological and solid tumors.
- Who are 恒赛生物's investors?
- 恒赛生物's investors include TriWise Capital.